outlin long-rang plan featur top-lin compound-annual-growth-rate
anoth bp op margin expans notabl compani expect new
product sale geograph expans contribut growth within
lrp view outlook compel consist bax vastli improv
updat view compris adjust oper margin vs
previous non-gaap ep rang
compani offer last juli get expect constant currenc
sale growth compound-annual-growth-rate acceler later period free
cash flow project oper cash flow compani
highlight improv free cash flow time
look target anticip adjust oper margin
non-gaap ep compani believ constant
currenc sale growth compound-annual-growth-rate step result averag
full period within next bp op margin improv
forecast bp come gross margin expans remain
bp stem oper cost reduct compani anticip free
cash flow oper cash flow plan capital-expenditure
note soon achiev rate free cash flow convers consist
doubl rate compani capit alloc strategi
remain consist reinvest busi first target dividend pay-out ratio
time engag intens focu return lastli buy back stock
compani revenu growth pois acceler
believ six therapeut area oper show combin weight
averag market growth rate compani think growth
compound-annual-growth-rate area period around achiev above-
market result everywher except pharmaceut expect share
compound-annual-growth-rate market largest segment renal target sale
compound-annual-growth-rate interv roughli bp ahead what expect total
market medic deliveri growth peg clinic nutrit
advanc surgeri acut therapi look
period whole anticip new product sale geograph expans
contribut growth within lrp amount bp growth
roughli bp come oper growth compani expect
new product revenu contribut total renal
medic deliveri account almost total project sale
contribut respect
pleas see page report import disclosur
compani split allow baxter better focu deliv margin expans
top bottom line growth opportun longer term new baxter
hamper low singl digit top line growth trajectori lower oper
ebitda margin profil rel peer earli go clearer path forward
abl acceler top line growth better expect margin expans
opportun could bolster long-term outlook given top-lin margin profil
new baxter believ compani deserv trade premium med tech peer
current valuat keep us market perform
focus support compani
oper cash flow track grow
new tuck-in bolt-on acquisit
expect gener top-lin
gambro margin synergi deliv
improv ahead expect
om ebitda margin expans
opportun realiz sooner
pipelin opportun acquisit
contribut next five year
gambro margin synergi fail
meet key benchmark improv
om expans come
pipelin fail deliv
 fail produc new top-lin
diversifi global healthcar compani develop medic
devic product use hospit kidney dialysi center nurs home rehabilit
center clinic medic research laboratori patient in-hom use
biopharma solut also chronic acut product offer renal
divis gener total revenu medic product sale
complet acquisit gambro ab largest acquisit histori
bolster renal busi product portfolio juli spun bioscienc
divis form baxalta acquir shire
expect medic deliveri market grow around annual
believ medic deliveri busi grow compani hold
 posit iv therapi account roughli two-third current
medic deliveri sale player market infus system
pump dispos infus system suppli third
divis sale project new product revenu medic deliveri
compani meaning launch later year version nine sigma
spectrum pump platform call spectrum iq iter enhanc
respect auto-program featur two-way wireless connect
plan launch global new comprehens pump platform includ large-
volum syring pump compani intend enter new geographi infus
pump busi indic expans would broad-bas involv territori
within emea latin america asia pacif also want pursu long-term
develop initi broaden scope market special monitor
pain manag infect prevent
respect acut therapi believ global acut therapi market grow
around annual acut therapi busi grow
compani hold lead posit continu renal replac therapi
crrt organ support therapi account acut
therapi sale respect project new product revenu divis
compani believ prismax million-plu opportun
doubl organ support revenu stream year call sepsi
manag larg unmet medic need particip via filtrat devic
oxiri intend enhanc acut therapi portfolio digit health
initi use analyt enabl clinic insight drive util geograph
expans optimist compani leverag strong capit presenc
varieti high-margin therapi icu
hemostat sealant current account bax advanc surgeri
busi compani player market global advanc surgeri
market expect grow annual compani anticip
above-market growth interv intend gener
new product revenu includ enhanc floseal franchis
floseal prep agre bax depict signific opportun exist
thank clinic evid amass continu enhanc floseal
tisseal instanc floseal potenti annual save roughli
associ product cost benefit compani substanti
data notabl aim expand portfolio japan china
time-frame also highlight growth effort microsurgeri flow
coupler eventu launch venou arteri coupl compani
also address nerv repair neurotub product told think
potenti doubl annual revenu associ microsurgeri
manag forese renal busi grow
approxim new product revenu contribut forecast period
upcom product introduct highlight present kaguya japan
theranova theranova china point gener
gener manag enthusiast hdx product enabl
theranova product address end-stag renal diseas patient
succumb cardiovascular diseas clear larg urem toxin potenti reduct
inflamm atherosclerosi calcif kaguya system factor
acceler market penetr japan solut gener system poc
valuat price
product offer simplifi therapi cycl reduc patient treatment burden addit
new product innov focu market develop effort particular
focu emerg market compani plan address consum demand
afford access high eas use product hdx sharesourc focu
area invest pour clinic qol econom evid
anticip growth clinic nutrit busi includ
expect contribut new product among key upcom launch
pipelin oliclinomel china olimel finomel emea
clinimix olimel differenti offer highest protein
lowest glucos content current market clinimix hp offer
protein market altern finomel provid uniqu fish-blend
complement exist olive-blend portfolio market develop front
invest support therapi adopt differenti gener
addit clinic evid prove among factor optim feed
supplement parenter nutrit pn lead faster recoveri lower cost care
higher protein pn provid energi reduc ventil day icu
much day manag lrp growth assumpt also predic enter
project adjac market opportun adjac includ
neonat nutrit numeta product aim drive standard ready-to-us
pn first-lin therapi pre-term infant oncolog increas awar
olimel benefit oncolog patient subcutan administr
bax clinimix subq product help treat hospit elderli patient poor venou
access achiev optim nutrit lastli intend pursu transform mean
innov novel formul consist lipid amino acid blend improv
prep deliveri technolog servic enhanc highlight digit nutrit
pharma manag pursu greater penetr higher growth end market
gener inject effort increas bax current weight market growth
rate toward market rate confid achiev lrp
plan add increment new product revenu focus
develop broad portfolio key therapeut area among molecul
expect develop molecul specialti molecul oncolog
cardiovascular anti-infect anesthesia also continu invest
market develop initi leverag set differenti deliveri platform
target brand drug come patent lrp partial reli enter
adjac market leverag competit advantag expertis toward
develop complex drug formul among core compet underli
assumpt pharma busi compani strong hospit channel
drive penetr acceler share gain new product track record qualiti
patient safeti creat suppli continu custom satisfact robust capabl
support develop complex molecul global manufactur footprint
facilit low-cost product suppli flexibl
set valuat argument asid believ feasibl bax long-term project
reduc invest risk associ stock make outlook attract rel
peer struggl even full-year guidanc weve gotten favor
updat compani long-term target expect believ stock
driven mostli quarterli result see upsid current street project price
target share continu deriv appli valuat multipl
ep ebitda estim respect averag result
compani report cowen compani estim
year end decemb end decemb end decemb medic good gross gross net interest expens expens total expens incom incom tax incom tax incom oper ex intang restructur non-recur gain incom non-controlling intang amort inc inc oper ex-intang cowen
compani report cowen compani estim
compani report cowen compani estim
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
competit dynam global potenti regulatori delay potenti delay
time product launch emerg develop market econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend share repurchas fluctuat foreign exchang rate
compani specif risk includ impact long-act factor viii agent
global share advat franchis limit increas plasma fraction
capac ig franchis time regulatori approv hyq line-extens
bioscienc product develop realiz synergi impact margin
gambro acquisit acquisit exposur emerg market
